- ￥520
- 卡梅德/KMD Bioscience
- 天津
- KRP688
- 2026年01月26日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Avoid repeated freeze-thaw cycles.
- 英文名：
Recombinant Human PDGF-BB Protein
- 库存：
999
- 供应商：
卡梅德生物科技（天津）有限公司
- 规格：
20ug///50ug/// 100ug///200ug///1mg
| 产品编号 | KRP688 |
| 产品名称 | Recombinant Human PDGF-BB Protein |
| 别名 | 重组人PDGF-BB蛋白，PDGF-BB, PDGF-B, FLJ12858, PDGF2 |
| 产品简介 | 重组人血小板衍生生长因子-BB，是血管生成和间质细胞增殖的强效促进因子。主要用于血管生成研究、伤口愈合模型及间充质干细胞扩增。 |
| 分子名称 | PDGF-BB |
| 表达系统 | E.coli |
| 物种 | Human |
| 纯度 | >97%, determined by SDS-PAGE. |
| 应用 | WB, ELISA |
| 储存条件 | Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Avoid repeated freeze-thaw cycles. |
| 缓冲体系 | It is recommended that the lyophilized human PDGF-BB protein be dissolved in 4 mM HCl at a concentration of 100 μg/mL for further dilution as the working concentration. |
| 产品背景 | PDGF的一种同源二聚体形式，能与PDGFR-α和PDGFR-β两种受体高亲和力结合，是促有丝分裂和促血管生成作用最强的PDGF形式，在组织修复和血管生成中至关重要。 |
| 产品声明 | 该产品仅供科研使用，不可直接用于人体或注射。 |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Methods for Producing Recombinant Human Cellular Retinaldehyde-Binding Protein
The cellular retinaldehyde-binding protein (CRALBP) is expressed at high levels in vertebrate visual trssue, where it may serve to modulate the interaction of 11-cis -retinol with visual-cycle enzymes in the retinal pigment epithelium (RPE
Recombinant Protein Production in Yeasts
Recombinant protein production is a multibillion-dollar market. The development of a new product begins with the choice of a production host. While one single perfect host for every protein does not exist, several expression systems ranging
Recombinant Protein Expression in Nicotiana
Recombinant protein pharmaceuticals are now widely used in treatment of chronic diseases, and several recombinant protein subunit vaccines are approved for human and veterinary use. With growing demand for complex protein pharmaceuticals
技术资料暂无技术资料 索取技术资料
